Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/1b Study to Evaluate the Safety and Tolerability of AB598 Monotherapy and Combination Therapy in Participants With Advanced Malignancies

NCT05891171 is registered in ClinicalTrials.gov with Arcus Biosciences, Inc. as lead sponsor.

NCT NCT05891171
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05891171 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/1b Study to Evaluate the Safety and Tolerability of AB598 Monotherapy and Combination Therapy in Participants With Advanced Malignancies
Lead sponsor
Arcus Biosciences, Inc.
Phase
Phase 1
Overall status
Active, not recruiting
Start date
October 13, 2023
Completion date
September 30, 2027
Enrollment
40 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

advanced cancer, advanced malignancies, bladder cancer, cervical cancer, esophageal cancer, gastric cancer, gastroesophageal-junction cancer (gej), head and neck squamous cell carcinoma (hnscc), non-small cell lung cancer (nsclc), ovarian cancer, renal cell carcinoma (rcc), triple negative breast cancer (tnbc)